title: Pentigetide nasal solution: a multicenter study evaluating efficacy and safety in patients with seasonal allergic rhinitis.
abstract: The safety and efficacy of pentigetide (Pentyde) nasal solution, administered as 1 mg into each nostril four times daily, was compared with placebo for controlling symptoms associated with seasonal allergic rhinitis. This was a randomized, multicenter, double-blind, parallel-group trial involving 431 patients divided equally between pentigetide and placebo treatment. The study was conducted during the 1986 spring allergy season and consisted of 1 week of baseline followed by 2 weeks of treatment. Physicians evaluated the frequency and severity of nasal symptoms at study entry (day 1) and the final visit (day 22). Physicians and patients assessed the global condition of the patient at the end of the study and patients also recorded the severity of symptoms in a daily diary. Pentigetide-treated patients showed a statistically significant greater reduction in the frequency (P = .004) and severity (P = .05) of total nasal symptom score (sneezing, nasal congestion, and rhinorrhea) and in the individual nasal symptom scores compared with placebo-treated patients. Diary results showed consistently lower total nasal symptom scores on each treatment day for pentigetide-treated patients (P = .02). Both the physicians and patients globally rated more pentigetide-treated patients improved than placebo-treated patients. The incidence and types of adverse experiences were similar between treatment groups and there were no reports of sedation or fatigue in the pentigetide group. No clinically significant changes occurred for laboratory tests, physical examination parameters or vital sign measurements. Pentigetide nasal solution was safe and effective for the treatment of seasonal allergic rhinitis.
authors.affiliation: Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania.
authors.forename: H C
authors.initials: HC
authors.lastname: Mansmann
authors.forename: J
authors.initials: J
authors.lastname: Rosen
authors.forename: R
authors.initials: R
authors.lastname: Ziering
authors.forename: F
authors.initials: F
authors.lastname: Hampel
authors.forename: P
authors.initials: P
authors.lastname: Ratner
authors.forename: S
authors.initials: S
authors.lastname: Findlay
authors.forename: W
authors.initials: W
authors.lastname: Kniker
authors.forename: Z
authors.initials: Z
authors.lastname: Haddad
authors.forename: A
authors.initials: A
authors.lastname: Daigle
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index
chemical_list: D010446:Peptide Fragments; D007073:Immunoglobulin E; C040297:pentigide